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Pleural effusionAbstract Aim of the work: To evaluate the role of interleukin-6 (IL-6) in diagnosis of malignant
pleural mesothelioma by detecting its level in the pleural ﬂuid and serum of the patient with malig-
nant pleural mesothelioma in comparison with other causes of pleural effusion.
Materials and methods: This study was conducted on 44 patients (25 males and 19 females) with
pleural effusions of different etiologies, at Banha University Hospital from April 2011 to December
2012. These patients were classiﬁed according to their ﬁnal diagnosis into four groups: Group I:
included 20 cases with malignant pleural effusions secondary to malignant pleural mesothelioma.
Group II: included 7 cases with malignant pleural effusions secondary to metastatic adenocarci-
noma. Group III: included 7 cases with tuberculous pleural effusions. Group IV: included 10 cases
with transudative pleural effusions. IL-6 measured in both plasma and pleural ﬂuid of selected
patients and statistically analyzed.
Results: The mean values of pleural ﬂuid IL-6 were higher among patients with malignant effusion
(groups (I, II), respectively) than those with nonmalignant (groups (III, IV)), these differences were sta-
tistically signiﬁcant (p< 0.001). There was signiﬁcant increase in pleural ﬂuid IL-6 levels in group (I)
mesothelioma mean was (1627.4 ± 294.3) versus group (II) adenocarcinoma mean was
(1501.1 ± 274.2) p< 0.05 being higher in group (I). There was no signiﬁcant difference in the mean
levels of serum IL-6 in malignant groups (I, II), versus benign groups (III, IV) but there was a high sig-
niﬁcant increase in pleural ﬂuid IL-6 level inmalignant groups (I, II) meanwas (1590.7 ± 294.6) versus
benign groups (III, IV) mean value was (1260.6 ± 145.5). p< 0.001 being higher in malignant groups.
Conclusion: Pleural ﬂuid level of interleukin-6 can be used as diagnostic tool for malignant pleural
mesothelioma (MPM). Pleural ﬂuid level of interleukin-6 (IL-6) can be used in differentiatingmalignant
from non malignant effusions, pleural effusions secondary to malignant pleural mesothelioma (MPM)
from those secondary to Adenocarcinoma.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.
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Pleural effusions are often a diagnostic dilemma as the differ-
ential diagnosis is wide [1]. However, in about 5–10% of cases
the effusions remain undiagnosed after the initial evaluation
and 20% of these effusion are later proved to be malignant
[2]. Cytokines are proteins with relatively low molecular weight
that are secreted by cells in response to a variety of different
stimuli and act as key mediators of the host response to vari-
ous infections, inﬂammatory and immunologic challenges [3].
IL-6 is a pleiotropic cytokine stimulating a variety of cell types
[4]. Mesothelioma cells and cell lines have been reported to
produce IL-6 [5]. Since IL-6 is relatively stable and its concen-
trations can be measured in synovial or cerebrospinal ﬂuid the
measurement of IL-6 in the body ﬂuid would be useful to
determine the activity of inﬂammation in patient with compli-
cated conditions [6,7]. IL 6 role as an anti-inﬂammatory cyto-
kine is mediated through its inhibitory effects on TNF-alpha
and IL-1, and activation of IL 10 [8]. IL 6 plays a central role
in host defense against infection and tissue. IL 6 elicits cellular
actions by binding to the membrane bundle IL 6 receptor [7].
Because IL 6 is an autocrine growth factor for many cell
types, its hyperproduction has been associated with a variety
of malignancies including plastocytoma, multiple myeloma,
uterine cervical carcinoma and Kaposi’s sarcoma [9,10].
Patients and methods
This study was conducted on 44 patients with pleural effusions
of different etiologies, at Banha University Hospital from
April 2011 to December 2013 after approval of the study pro-
tocol by the Local Ethical Committee and obtaining written
fully informed patients’ consent. These patients were classiﬁed
according to their ﬁnal diagnosis into four groups: Group I:
malignant pleural effusions secondary to malignant pleural
mesothelioma. Group II: malignant pleural effusions sec-
ondary to metastatic adenocarcinoma. Group III: tuberculous
pleural effusions. Group IV: transudative pleural effusions.
Exclusion criteria
1. Any effusion due to undetermined cause or suspected to
have more than one possible cause.
2. Minimal effusions.
3. Patients already started any kind of treatment.
All patients were subjected to the following: (1) Full medi-
cal history and clinical examination, routine laboratory inves-
tigations, radiological examination (CXR & CT chest),
abdominal ultrasonography, echocardiography whenever
needed. (2) Tuberculin skin test and Sputum examination for
acid fast bacilli (AFB) by Ziehl–Neelsen stain. 3-Fiber-optic
bronchoscopy: for patients with suspected bronchogenic carci-
noma where tissue biopsies or bronchoalveolar lavage (BAL)
was sent for histopathological examination. Diagnostic thora-
cocentesis: was done to all patients for physical, chemical, bac-
teriological examination and cytological examination.
Quantitative measurement of pleural ﬂuid IL-6 and using
ELISA technique. Pleural biopsies: were taken for all patients
in groups (I, II, and III). Venous blood samples for quantita-
tive estimation of serum IL-6. Quantitative measurement ofIL-6 in serum and pleural ﬂuid using ELISA kit supplied by
KOMA BIOTECH INC. Catalog No. K03394.
Statistical analysis
The collected data were analyzed using SPSS version 16 soft
ware. Chi square test (v2), student ‘‘t’’ test and ANOVA were
used as tests of signiﬁcance. ROC curve was used to detect cut-
off values of IL-6 with optimum sensitivity and speciﬁcity.
Stepwise multiple regression analysis was done to detect the
signiﬁcant predictors of IL-6.Results
The mean of age (in years) of group I was 65.9 ± 12.4, group
II was 65 ± 9.8, group III was 53.1 ± 6.94 and group IV was
62 ± 8.5 years with male predominance 56.8%. The most
common presenting complaints were shortness of breath
(n= 42 cases, 95.5%) followed by cough that occurred in
(n= 41 cases, 93%), then chest pain (n= 38 cases, 86.4%),
fever (n= 12 cases, 27.3%) and hemoptysis (n= 6 cases,
13.6%). The classic radiographic picture was homogenous
opacity with concave upper border rising toward the lateral
chest wall it may be moderate sized effusions (n= 19 cases,
44.2%), while cases with massive effusion showed complete
or near complete opaciﬁcation (n= 15 cases, 34.9%), and
mild effusion (n= 9 cases, 20.9%). Right side effusions were
27 cases, 62.8%, left-sided 11 cases 25.6% and bilateral 5 cases
11.6%. Tuberculin skin test was positive in 3 cases in group (I)
mesothelioma representing 15%, and 7 cases in group (III) TB
representing 100% and lastly all cases were negative in group
(II adenocarcinoma, IV control). The mean levels of platelets
was higher in mesothelioma (I) followed by TB effusion (III)
and lastly adenocarcinoma (II) versus group (IV) and these
was signiﬁcance difference as p< 0.001.
The mean values of serum and pleural ﬂuid protein levels
were as the following: group (I) (4.47 ± 0.77 and
3.9 ± 0.82 g/dl), respectively, in group (II) (4.35 ± 0.76 and
4.7 ± 1.01 g/dl), respectively, in group (III) (3.94 ± 0.60 and
4.2 ± 0.50 g/dl) the ratios of PLF/SPtn were always more than
0.5 in the three exudative groups. While in group (IV)
(4.8 ± 0.89 and 2.3 ± 0.48 g/dl), respectively, and the ratios
of PLF/Sptn were always less than 0.5.
The mean values of serum and pleural ﬂuid LDH levels were
as following: group (I) (109.9 ± 16.7 and 1107.6 ± 296.8 U/L),
respectively, in group (II) (117.0 ± 12.9 and 927.5 ± 388.2 U/
L). In group (III) (102.0 ± 11.8 and 805.8 ± 330.8 U/L),
respectively. and the ratios of FLDH/SLDH were more than
0.6 and the absolute values of FLDH were more than
200 IU/L and more than 2/3 of the upper limit of the serum
in the three exudative groups. While in group (IV) control,
the mean levels was (276.6 ± 35.9 and 194.2 ± 29.7 IU/L),
respectively, and the ratio of FLDH/SLDH was less than 0.6
and the absolute values of FLDH were less than 200 IU/L
and less than 2/3 of the upper limit of normal serum.
As regard glucose level in serum and pleural ﬂuid the lowest
mean level of pleural ﬂuid glucose was found in tuberculous
pleural effusion (52.5 ± 20.5) followed by pleural effusion sec-
ondary to mesothelioma (54.7 ± 28.9) then pleural effusion
secondary to adenocarcinoma (68.3 ± 17.2) and lastly tran-
sudative effusion (72 ± 22.8).
Figure 1 The mean levels of pleural ﬂuid, and serum IL-6 among
exudative and transudative effusion are shown.
Figure 2 The mean level of pleural IL-6 among the studied
groups are shown.
Table 1 Represents descriptive statistics as regard the mean levels of pleural ﬂuid and serum IL-6 among exudative and transudative
effusion.
Group Exudates eﬀusion (N= 34) Transudate eﬀusion (N= 10) Student ‘‘t’’ p
Mean ±SD Mean ±SD
Parameter
Serum IL-6 291.7 100.97 134.6 20.95009 4.8 <0.001*
Pleural ﬂuid IL-6 1521.6182 299.79 1257.6 155.72182 2.7 0.01*
Role of interleukin-6 421There was no signiﬁcant difference in the mean levels of
serum IL-6 in exudative effusions (mean was 291.7 ± 100.9),
versus transudative effusions (mean was 134.6 ± 20.95)
p< 0.01. But there was a high signiﬁcant increase in pleural
ﬂuid IL-6 level in exudative effusions (mean was
1521.6 ± 299.7) versus transudative effusions (mean was
1257.6 ± 155.7) p< 0.01 being higher in exudative effusions
(Table 1, Fig. 1).
Also there were high signiﬁcant increases in pleural ﬂuid
IL-6 level in group (I), (II), mean values were
(1627.4 ± 294.3) (1501.1 ± 274.2), respectively, versus tran-
sudative effusions group (IV) mean value was
(1257.7 ± 155.2) being higher in group (I, II) (Table 2,
Fig. 2).
Also there was signiﬁcant increase in pleural ﬂuid IL-6 in
group (III) mean value was (1264.8 ± 141.2) versus transuda-
tive effusions group (IV) mean value was (1257.7 ± 155.2)
p< 0.05 being higher in group (III). p< 0.01 (Table 2, Fig. 2).
There was signiﬁcant increase in pleural ﬂuid IL-6 levels in
group (I) mesothelioma mean was (1627.4 ± 294.3) versusTable 2 Represents descriptive statistics as regards the mean level
Group N Mean Std. Dev
Mesothelioma (I) 20 1627.41,2 294.33609
Adenocarcinoma (II) 7 1501.1 274.29342
TB eﬀusion (III) 7 1264.8 141.75964
Transudative eﬀusion (IV) 10 1257.7 155.72182
Total 44 1465.6 292.65728
1 Signiﬁcants in comparison to TB effusion group.
2 Signiﬁcants in comparison to transudative effusion group.group (II) adenocarcinoma mean was (1501.1 ± 274.2)
p< 0.05 being higher in group (I) (Table 2, Fig. 2).
There was no signiﬁcant difference in the mean levels of
serum IL-6 in malignant groups (I, II), versus benign groups
(III, IV) mean values were (282.5 ± 106.8 and
213.29 ± 107.44), respectively, p< 0.045, but there was a high
signiﬁcant increase in pleural ﬂuid IL-6 level in malignant
groups (I, II) mean was (1590.7 ± 294.6) versus benign groups
(III, IV) mean value was (1260.6 ± 145.5). p< 0.001 being
higher in malignant groups (Table 3, Fig. 3).
In the present study (Table 4, Fig. 4) using a cutoff point of
1426.4 pg/ml pleural ﬂuid IL-6 can be used to differentiate
pleural effusion secondary to malignant mesothelioma from
pleural effusion secondary to metastatic adenocarcinoma with
sensitivity 85%, speciﬁcity 83%, PPV 81%, NPV 87%,
respectively.
In the present study (Table 5, Fig. 5) using a cutoff point of
>1317.92 pleural ﬂuid IL-6 can differentiate malignant pleural
effusions from non-malignant pleural effusions with sensitivity
76.9%, speciﬁcity 70.6%, PPV 80%, NPV 66.7%, respectively.of pleural IL-6 (pg/ml) among the studied groups.
Minimum Maximum ANOVA p
900.60 1990.30




Figure 4 ROC curve for the performance of IL-6 in diagnosis of
mesothelioma.
Table 3 Represents descriptive statistics as regards the mean levels of pleural ﬂuid and serum IL-6 in malignant versus non malignant.
Group Malignant eﬀusion (N= 27) Non malignant eﬀusion (N= 17) Student ‘‘t’’ p
Mean ±SD Mean ±SD
Parameter
Serum IL-6 282.5 106.8 213.29 107.44 2.1 0.045*
Pleural ﬂuid IL-6 1590.7 294.6 1260.63 145.56 4.3 <0.001*
Figure 3 The mean levels of pleural ﬂuid, and serum IL-6 in
malignant versus non malignant are shown.
422 R. El Sayed et al.In the present study (Table 6) using a cutoff point of >7.5
as ratio between pleural and serum levels of Interleukin-6 can
diagnose transudative effusion, if the ratio <7.5 can diagnose
exudative effusion with sensitivity 100%, speciﬁcity 79.4%,
PPV 58%, NPV 100%, respectively.
Discussion
Cytokine – producing cells and cytokines have been reported
in pleural effusions from patients with malignant diseases,
tuberculosis and empyema 10 interleukin-6 is a multifunctional
cytokine secreted by lymphoid and non lymphoid cells that
regulates B-cell and T-cell function and is a potent inducer
of the acute – phase protein response, IL-6 is often used as a
marker for systemic activation of proinﬂammatory cytokines
(Opal and DePalo) [3].
This study was done to assess the role of interleukin-6 in
differentiation of pleural effusion secondary to malignant
mesothelioma, metastatic adenocarcinoma and tuberculous
infection, as well as to ﬁnd out a minimal invasive tool for
differentiating the above mentioned causes of pleural
effusion.
In the present study (Table 1, Fig. 1), there was no signiﬁ-
cant difference in the mean levels of serum IL-6 in exudative
effusions (mean was 291.7 ± 100.9), versus transudative
effusions (mean was 134.6 ± 20.95) p< 0.01. But there wasTable 4 Showing cutoff value, sensitivity, speciﬁcity, positive pr
mesothelioma.
Cutoﬀ value Sensitivity (%) Speciﬁcity (%) PP
Serum IL-6 (172.2) 100 41.7 58.
Pleural IL-6 (1426.4) 85 83.6 81a high signiﬁcant increase in pleural ﬂuid IL-6 level in exuda-
tive effusions (mean was 1521.6 ± 299.7) versus transudative
effusions (mean was 1257.6 ± 155.7) p< 0.01 being higher
in exudative effusions.
Also there were high signiﬁcant increases in pleural
ﬂuid IL-6 level in group (I), (II), mean values were
(1627.4 ± 294.3) (1501.1 ± 274.2) respectively versus tran-
sudative effusions group (IV) mean value was
(1257.7 ± 155.2) being higher in group (I, II) (Table 2, Fig. 2).
Also there was signiﬁcant increase in pleural ﬂuid IL-6 in
group (III) mean value was (1264.8 ± 141.2) versus transuda-
tive effusions group (IV) mean value was (1257.7 ± 155.2)
p< 0.05 being higher in group (III). p< 0.01 (Table 2, Fig. 2).
This results matched with the results of Akarsu et al. [11]
who reported that a panel of interleukins including IL-6 could
be used in pleural ﬂuid exudates and transudate distinction
where they detected that IL-6 levels were 1858.5 ± 363.1 pg/
ml in the exudate groups and 656.5 ± 160.9 pg/ml in the tran-
sudate groups p< 0.01. Although, the signiﬁcance of pleural
ﬂuid IL-6 in differentiating exudates from transudates came
in agreement with the results of Xirouchaki et al. [10] whoedictive value of pleural ﬂuid and serum IL-6 in diagnosis of
V (%) NPV (%) AUC 95% CI (AUC) p
8 100.0 0.44 0.25–0.64 0.53
87 0.81 0.66–0.95 0.001*
Table 5 Showing sensitivity, speciﬁcity, positive predictive value of pleural ﬂuid and serum IL-6 in diagnosis of malignant effusion.
Cutoﬀ value Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) AUC 95% CI (AUC) p
Serum IL-6 (172.2) 100 58.8 78.8 100.0 0.704 0.52–0.89 0.025*
Pleural IL-6 (1317.95) 76.9 70.6 80 66.7 0.84 0.71–0.96 0.001*
Figure 5 ROC curve for the performance of IL-6 in diagnosis of
malignant effusion.
Role of interleukin-6 423reported that pleural ﬂuid IL-6 is an accurate mean of distin-
guishing exudates from transudates. but the signiﬁcance of
serum IL-6 did not come hand in hand with our results where
they found signiﬁcant difference between the mean values of
serum IL-6 when compared transudates versus exudates being
higher in exudates also our results regarding serum IL-6 did
not match with the results of Hsieh et al. [12] who found sig-
niﬁcant difference between the mean levels of serum IL-6 in
exudates compared to transudates being higher in exudates.
The explanation of not ﬁnding signiﬁcant difference in
serum IL-6 between exudates and transudates and that there
was signiﬁcant increase in pleural ﬂuid IL-6 than serum levels
was reported by Marie et al. [13] who mentioned that cytokines
can be trapped by the surrounding cells in their environment,
measurable levels of cytokines in biological ﬂuids represent the
‘‘tip of the iceberg’’. Also Hoheisel et al. [14] conclude that ele-
vated levels of IL-6 in pleural effusions are due to compart-
mentalization at the site of active disease. While Kiropoulos
et al. [15] related this ﬁnding to local production of this pro-in-
ﬂammatory cytokine (IL-6).
In the present study (Table 2, Fig. 2) there was signiﬁcant
increase in pleural ﬂuid IL-6 levels in group (I) mesothelioma
mean was (1627.4 ± 294.3) versus group (II) adenocarcinomaTable 6 Showing cutoff value, sensitivity, speciﬁcity, positive pre
diagnosis of type of pleural effusion either exudates or transudates.
Cutoﬀ value for transudate Sensitivity Speciﬁcity AU
Ratio (7.5) 100% 79.4% 0.9
Ratio P7.5 can diagnose transudative effusion with sensitivity 100%, AU
Ratio <7.5 can diagnose exudative effusion.mean was (1501.1 ± 274.2) p< 0.05 being higher in group (I),
these results matched with results of Nakano et al. [16] who
reported that level of pleural ﬂuid IL-6 in patients with malig-
nant pleural effusions secondary to mesothelioma were
signiﬁcantly higher than in patients with adenocarcinoma.
These results did not match with those of Yamaguchi et al.
[17] who reported that IL-6 were elevated in effusions sec-
ondary to metastatic adenocarcinoma with mean values of
2970.5 pg/ml.
In the present study (Table 3, Fig. 3) there was no
signiﬁcant difference in the mean levels of serum IL-6 in malig-
nant groups (I, II), versus benign groups (III, IV) mean values
were (282.5 ± 106.8, and 213.29 ± 107.44), respectively,
p< 0.045, but there was a high signiﬁcant increase in pleural
ﬂuid IL-6 level in malignant groups (I, II) mean was
(1590.7 ± 294.6) versus benign groups (III, IV) mean value
was (1260.6 ± 145.5). p< 0.001 being higher in malignant
groups.
These results came in agreement with those of Yamaguchi
et al. [17] who reported that marked elevation of IL-6 was
found in all of malignant pleural effusions. It ranged from
77.5 to 54.1 pg/ml. being far above the increased levels in the
paired serum. Also Alexanderkis et al. [18] reported that pleu-
ral ﬂuid concentrations of IL-6 were higher in malignant effu-
sion group A versus group B (non malignant effusion) and
group C (transudative effusion) p< 0.01.
In the present study (Table 4, Fig. 4) using a cutoff point of
1426.4 pg/ml pleural ﬂuid IL-6 can be used to differentiate
pleural effusion secondary to malignant mesothelioma from
pleural effusion secondary to metastatic adenocarcinoma with
sensitivity 85%, speciﬁcity 83%, PPV 81%, NPV 87%,
respectively.
In the present study (Table 5, Fig. 5) using a cutoff point of
>1317.92 pleural ﬂuid IL-6 can differentiate malignant pleural
effusions from non-malignant pleural effusions with sensitivity
76.9%, speciﬁcity 70.6%, PPV 80%, NPV 66.7%, respectively.
In the present study (Table 6) using a cutoff point of >7.5
as ratio between pleural and serum levels of Interleukin-6 can
diagnose transudative effusion, if the ratio <7.5 can diagnose
exudative effusion with sensitivity 100%, speciﬁcity 79.4%,
PPV 58%, NPV 100%, respectively.dictive value of ratio between pleural ﬂuid and serum IL-6 in
C NPV PPV 95% CI (AUC) p
25 100% 58.8% 0.85–1.0 <0.001*
C 0.925 p< 0.001.
424 R. El Sayed et al.Conclusions
Pleural ﬂuid level of interleukin-6 can be used as diagnostic
tool for malignant pleural mesothelioma (MPM). Pleural ﬂuid
level of interleukin-6 (IL-6) can be used in differentiating
malignant from non malignant effusions, pleural effusions sec-
ondary to malignant pleural mesothelioma (MPM) from those
secondary to Adenocarcinoma.Conﬂict of interest
No conﬂict of interest.
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